{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:23:12Z","timestamp":1785392592385,"version":"3.55.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","joms.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Oral and Maxillofacial Surgery"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.joms.2013.03.019","type":"journal-article","created":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T15:42:26Z","timestamp":1367422946000},"page":"1532-1540","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Combination of Zoledronic Acid and Targeted Therapy Is Active But May Induce Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Carcinoma"],"prefix":"10.1016","volume":"71","author":[{"given":"Torben","family":"Smidt-Hansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troels B.","family":"Folkmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Fode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Agerbaek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frede","family":"Donskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.joms.2013.03.019_bib1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1053\/j.seminoncol.2010.06.001","article-title":"Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer","volume":"37","author":"Saad","year":"2010","journal-title":"Semin Oncol"},{"key":"10.1016\/j.joms.2013.03.019_bib2","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/cncr.11571","article-title":"Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma","volume":"98","author":"Lipton","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.joms.2013.03.019_bib3","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bone.2010.09.008","article-title":"Skeletal complications and survival in renal cancer patients with bone metastases","volume":"48","author":"Woodward","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.joms.2013.03.019_bib4","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ctrv.2011.06.011","article-title":"Skeletal metastasis in renal cell carcinoma: Current and future management options","volume":"38","author":"Wood","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.joms.2013.03.019_bib5","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/annonc\/mdq554","article-title":"Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib","volume":"22","author":"Beuselinck","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.joms.2013.03.019_bib6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-5347(01)67218-5","article-title":"Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers","volume":"154","author":"Mani","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.joms.2013.03.019_bib7","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial\u2014The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.joms.2013.03.019_bib8","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2013.03.019_bib9","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","volume":"23","author":"Hoff","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2013.03.019_bib10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00256-008-0549-x","article-title":"Osteonecrosis of the jaw","volume":"38","author":"Reid","year":"2009","journal-title":"Skeletal Radiol"},{"key":"10.1016\/j.joms.2013.03.019_bib11","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.joms.2013.03.019_bib12","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/bjc.2012.385","article-title":"Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases","volume":"107","author":"Beuselinck","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.joms.2013.03.019_bib13","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.tripleo.2010.04.049","article-title":"Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: Presentation of three cases","volume":"110","author":"Hoefert","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.joms.2013.03.019_bib14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bone.2008.08.132","article-title":"Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma","volume":"44","author":"Brunello","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.joms.2013.03.019_bib15","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/annonc\/mdn788","article-title":"Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: Cumulative toxicity profile?","volume":"20","author":"Ayllon","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.joms.2013.03.019_bib16","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000313680","article-title":"Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib","volume":"33","author":"Bozas","year":"2010","journal-title":"Onkologie"},{"key":"10.1016\/j.joms.2013.03.019_bib17","first-page":"952","article-title":"Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: Two case reports","volume":"16","author":"Agrillo","year":"2012","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.joms.2013.03.019_bib18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10006-010-0224-y","article-title":"Osteonecrosis of the jaw related to sunitinib","volume":"15","author":"Koch","year":"2011","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2013.03.019_bib19","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.tripleo.2011.06.023","article-title":"Sunitinib related osteonecrosis of jaw: A case report","volume":"113","author":"Fleissig","year":"2012","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.joms.2013.03.019_bib20","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3109\/00365590903295193","article-title":"Bisphosphonate (zoledronic acid)-induced osteonecrosis of the jaw","volume":"43","author":"Haidar","year":"2009","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.joms.2013.03.019_bib21","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ejca.2012.02.050","article-title":"Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma","volume":"48","author":"Keizman","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.joms.2013.03.019_bib22","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","article-title":"Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma","volume":"17","author":"Motzer","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.joms.2013.03.019_bib23","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.joms.2013.03.019_bib24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1747-4477.2009.00213.x","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw\u20142009 Update","volume":"35","author":"Ruggiero","year":"2009","journal-title":"Aust Endod J"},{"key":"10.1016\/j.joms.2013.03.019_bib25","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/j.juro.2006.07.053","article-title":"Antitumor effects of amino bisphosphonates on renal cell carcinoma cell lines","volume":"176","author":"Pandha","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.joms.2013.03.019_bib26","first-page":"2949","article-title":"Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases","volume":"60","author":"Boissier","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.joms.2013.03.019_bib27","first-page":"3890","article-title":"Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices","volume":"57","author":"Boissier","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.joms.2013.03.019_bib28","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","article-title":"Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid","volume":"302","author":"Wood","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.joms.2013.03.019_bib29","doi-asserted-by":"crossref","first-page":"43603","DOI":"10.1074\/jbc.M308114200","article-title":"Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: Evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B\/Akt","volume":"278","author":"Bezzi","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.joms.2013.03.019_bib30","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1158\/1078-0432.CCR-07-0551","article-title":"Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients","volume":"13","author":"Santini","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.joms.2013.03.019_bib31","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1089\/jir.2005.25.144","article-title":"Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients","volume":"25","author":"Vincenzi","year":"2005","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.joms.2013.03.019_bib32","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-03-0325","article-title":"Zoledronic acid inhibits visceral metastases in the 4T1\/luc mouse breast cancer model","volume":"10","author":"Hiraga","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.joms.2013.03.019_bib33","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1359\/jbmr.1999.14.12.2048","article-title":"Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment","volume":"14","author":"Derenne","year":"1999","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2013.03.019_bib34","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2003-05-1655","article-title":"Induction of gamma-delta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in\u00a0vivo","volume":"102","author":"Dieli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.joms.2013.03.019_bib35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.9-90004-3","article-title":"Bisphosphonates: Preclinical review","volume":"9","author":"Green","year":"2004","journal-title":"Oncologist"},{"issue":"suppl 7; abstr 388","key":"10.1016\/j.joms.2013.03.019_bib36","article-title":"Fuhrman grade and concomitant bisphosphonates as additional prognostic factors in metastatic renal cell carcinoma with bone metastases treated with sunitinib","volume":"29","author":"Beuselinck","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.joms.2013.03.019_bib37","doi-asserted-by":"crossref","unstructured":"Yasuda Y, Fujii Y, Yuasa T, et al: Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma. Int J Clin Oncol. http:\/\/dx.doi.org\/10.1007\/s10147-012-0472-y; 2012.","DOI":"10.1007\/s10147-012-0472-y"},{"key":"10.1016\/j.joms.2013.03.019_bib38","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s00432-010-0907-7","article-title":"Bisphosphonate-induced osteonecrosis of the jaw: A review of 2,400 patient cases","volume":"136","author":"Filleul","year":"2010","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.joms.2013.03.019_bib39","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2013.03.019_bib40","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.critrevonc.2006.12.005","article-title":"Critical review: Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients\u2014May 2006","volume":"62","author":"Weitzman","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.joms.2013.03.019_bib41","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"}],"container-title":["Journal of Oral and Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278239113003091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278239113003091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T16:41:54Z","timestamp":1759509714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278239113003091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0278239113003091"],"URL":"https:\/\/doi.org\/10.1016\/j.joms.2013.03.019","relation":{},"ISSN":["0278-2391"],"issn-type":[{"value":"0278-2391","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of Zoledronic Acid and Targeted Therapy Is Active But May Induce Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Oral and Maxillofacial Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.joms.2013.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}